Bristol-Myers Drops After Lung-Cancer Drug Study Fails
Bloomberg News

Shares of Bristol-Myers Squibb Co. (BMY)  fell Tuesday, Nov. 27, after the drugmaker revealed a lung-cancer study it had been working on had failed.

Bristol Myers was down 3.8% to $50.75 after the company said a clinical study using a combination of the drugs Opdivo and Yervoy didn't significantly improve survival rates in patients with extensive-stage small cell lung cancer vs. placebo.

#MEDIA: We announced topline results from our small cell lung cancer program https://t.co/OnKArPx4sv pic.twitter.com/00TuS1QqVB

— Bristol-Myers Squibb (@bmsnews) November 26, 2018

Shares of Bristol-Myers hit a 52-week high of $70.05 back in February before slipping down to $51.17 in April. It then recovered through the start of October, rising to $63.23 on Oct. 8, before dropping to $48.83 on Oct. 24.  

More from Investing

China Halts Auto Tariffs, Tesla Lowers Prices of Model S, X

China Halts Auto Tariffs, Tesla Lowers Prices of Model S, X

AES Could Reach $27 Next Year; Cramer and the Charts Are Bullish

AES Could Reach $27 Next Year; Cramer and the Charts Are Bullish

Johnson & Johnson Shares Plunge After Report It Knew of Asbestos in Baby Powder

Johnson & Johnson Shares Plunge After Report It Knew of Asbestos in Baby Powder

Jim Cramer: Here's the State of Play as We Head Into Next Week's Action

Jim Cramer: Here's the State of Play as We Head Into Next Week's Action

Johnson & Johnson Breaks Down Sharply on the Charts So Take Action

Johnson & Johnson Breaks Down Sharply on the Charts So Take Action